James Knight, MD
Critical Care Medicine · Corvallis, ORNPI 1245402320
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,150 of the $1,545 with a category attached, or 74.4%. It is spread thinly across 21 manufacturers, the largest accounting for just 16.8%. Reporting peaked in 2022 at $402 and has fallen 91.7% since, to $33 in 2025.
Across 58 payments — averaging $26.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$259
- Regeneron Healthcare Solutions, Inc.$211
- Insmed, Inc.$160
- AstraZeneca$137
- GSK$105
- Sanofi-aventis U.S. LLC$97
- plus $576 from 15 others
What the payments were for
- Food & beverage$1,15074%
- Education$39526%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 8 | $259 |
| Regeneron Healthcare Solutions, Inc. | 5 | $211 |
| Insmed, Inc. | 6 | $160 |
| AstraZeneca | 6 | $137 |
| GSK | 7 | $105 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| Genentech USA, Inc. | 3 | $77 |
| Exthera Medical Corporation | 1 | $74 |
| Actelion Pharmaceuticals US, Inc. | 3 | $62 |
| Boehringer Ingelheim | 2 | $50 |
| Philips North America LLC | 3 | $47 |
| Sanofi | 2 | $40 |
| Vifor Pharma, Inc. | 1 | $39 |
| Baxter Healthcare | 2 | $34 |
| Shire North American Group Inc | 2 | $31 |
| Medtronic | 1 | $27 |
| Pinnacle Biologics, Inc | 1 | $24 |
| Novartis | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Grifols USA, LLC | 1 | $16 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYVASO$109
How this compares
$1,545 in reported general payments places this provider in the 80th percentile of 60 critical care medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breo ElliptaFluticasone/Vilanterol | 114 | $51,865 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 42 | $26,743 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $16,605 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $6,012 |
| DuleraMometasone/Formoterol | 12 | $4,061 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 12 | $3,659 |
| Ipratropium Bromide | 88 | $2,537 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 50 | $1,277 |
| Montelukast Sodium | 39 | $359 |
| Azithromycin | 56 | $348 |
| Prednisone | 34 | $85 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta, Anoro Ellipta, Trelegy Ellipta | $105 | $95,213178 claims |
| Boehringer IngelheimCombivent Respimat | $50 | $6,01213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 60 critical care medicine providers in Oregon.
Other critical care medicine in Corvallis
- Brian DelmonacoCorvallis$2K
- Susan ChoCorvallis$142
- Yelena RubinchikovaCorvallis$130
- Somnath GhoshMedford$11K
- Juan Tamariz LoorBend$7K
- Catherine HoughPortland$3K
- Rishi AroraMedford$3K
- Makoto UchiyamaTualatin$3K
- Jeffrey GoldPortland$2K
- Matthew NolandPortland$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.